gemifloxacin dual targeted fluoroquinolone potent vitro activity negative atypical human considered important causes respiratory tract infections gemifloxacin demonstrates impressive minimal inhibitory concentrations mic NUMBER values clinical isolates streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis chlamydia pneumoniae legionella spp mic NUMBER values reported NUMBER NUMBER NUMBER respectively gemifloxacin active vitro broad range bacilli mic NUMBER values enterobacteriaceae range NUMBER NUMBER escherichia coli providencia stuartii respectively majority genus having mic NUMBER drug concentrations NUMBER vitro activity gemifloxacin anaerobic organisms variable mic values gemifloxacin affected production penicillin macrolide resistance s pneumoniae gemifloxacin approved fda clinically efficacious resistant s pneumoniae pharmacokinetics gemifloxacin drug administered orally yield achieve sustainable drug concentrations exceeding mic values clinically important organisms gemifloxacin shown target dna gyrase preferred target topoisomerase iv secondary target enzymes critical dna replication organism survival clinical isolates s pneumoniae dual targeting activity thought important reducing likelihood selecting quinolone resistance gemifloxacin investigated approved therapy patients pneumonia cap acute exacerbations chronic bronchitis study patients receiving gemifloxacin compared clarithromycin remained free exacerbations longer periods time p NUMBER gemifloxacin shorter time eradication h influenzae did clarithromycin p NUMBER efficacy studies gemifloxacin adverse profile comparable compounds frequent effects diarrhoea abdominal pain headache gemifloxacin welcomed addition currently available agents treatment lower respiratory tract infections potential indications appear spectrum compound gram positive pathogens pathogens community acquired NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER gram negative beta lactamase multi drug daily community acquired community acquired microg ml microg ml microg ml